BRD2 bromodomain-mediated regulation of cell state plasticity modulates therapy response in glioblastoma
Our study identifies BRD2 as a key mediator of MES transition in GBM, with its bromodomains playing a crucial role in driving cell state plasticity. Targeting BRD2 with BD2-selective inhibitors offers a promising therapeutic strategy to overcome radiation resistance and improve outcomes for GBM patients.
Authors
- David A. Nathanson (ORCID: https://orcid.org/0000-0002-4919-9159)
- Yuvreet Kaur (ORCID: https://orcid.org/0000-0001-9606-3660)
- Nidhi Nathwani
- Albert S. Baldwin (ORCID: https://orcid.org/0000-0003-1246-1333)
- Anu Banerjee (ORCID: https://orcid.org/0000-0002-9657-4839)
- Frank B. Furnari (ORCID: https://orcid.org/0000-0003-1909-4361)
- Raghavendra Vadla (ORCID: https://orcid.org/0000-0002-3903-2662)
- Donald P. Pizzo (ORCID: https://orcid.org/0000-0002-8022-3604)
- Daisuke Kawauchi (ORCID: https://orcid.org/0000-0002-7679-173X)
- C Ryan Miller
- Philip Pham
- Brett M. Taylor (ORCID: https://orcid.org/0000-0002-4746-7228)
- Brandon M Jones (ORCID: https://orcid.org/0000-0002-5790-0216)
- Yohei Miyake (ORCID: https://orcid.org/0009-0000-7713-4419)
- Jonathan Tsang (ORCID: https://orcid.org/0000-0003-3811-7039)
- Benjamin Lin (ORCID: https://orcid.org/0000-0001-9361-5917)
- Shunichiro Miki (ORCID: https://orcid.org/0000-0002-9625-8668)
Institutions
- University of North Carolina at Chapel Hill (US)
- University of California, Los Angeles (US)
- University of Alabama at Birmingham (US)
- University of California San Diego (US)
- Sanford Consortium for Regenerative Medicine (US)
- Los Angeles Medical Center (US)
- University of California San Diego Medical Center (US)
- La Jolla Bioengineering Institute (US)
- UNC Lineberger Comprehensive Cancer Center
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-07-19
- DOI
- https://doi.org/10.1093/neuonc/noaf169
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00